SOLIGENIX, INC. Deferred Costs, Noncurrent
SOLIGENIX, INC. (SNGX) had Deferred Costs, Noncurrent of $17.87 thousand as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2024-03-15
- 2023-09-30: Deferred Costs, Noncurrent $17.87K.
- 2023-06-30: Deferred Costs, Noncurrent $17.87K.
- 2023-03-31: Deferred Costs, Noncurrent $20.15K.
- 2022-12-31: Deferred Costs, Noncurrent $20.21K.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2023-09-30 | $17.87K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $17.87K 10-Q · filed 2023-08-21 |
| 2023-03-31 | $20.15K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $20.21K 10-K · filed 2024-03-15 |
| 2022-09-30 | $20.27K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $20.27K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $20.27K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $20.27K 10-K · filed 2023-03-31 |
| 2021-09-30 | $20.65K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $5.80K 10-Q · filed 2021-08-13 |
| 2020-12-31 | $53.52K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |